In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Pharmaceutical
CNS specialist Minerva Neurosciences lost 59% of its stock market value on Tuesday. 28 February 2024
Biotechnology
US neurodegenerative diseases focussed biotech Denali Therapeutics saw its shares rocket more than 38% to $23.35, on news of a $500 million private placement. 28 February 2024
Pharmaceutical
Belgium’s largest drugmaker UCB today reported earnings results for the full year ended December 31, 2023 with a downturn on sales and earnings, but demonstrating significant achievements and sending its shares up 3.5% to 100.50 euros. 28 February 2024
Pharmaceutical
Shares of biotech FibroGen leapt 14.6% to $2.12 by close of trading Tuesday, after it announced a deal with UK pharma major AstraZeneca for roxadustat would be terminated. 28 February 2024
Biotechnology
France-based ophthalmology biotech PulseSight Therapeutics launches today with seed finance from Pureos Bioventures and ND Capital. 28 February 2024
Pharmaceutical
French ophthalmology company Nicox has announced it will replace its chief executive, Andreas Segerros, with current chief business officer Gavin Spencer. 28 February 2024
Pharmaceutical
In the USA, there is growing resistance to a bid from the White House to exercise so-called march-in rights, a process whereby the federal government requires patent holders to agree to a licence. 27 February 2024
Pharmaceutical
Antiviral specialist Gilead Sciences has announced a new approval from the US Food and Drug Administration, for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide). 27 February 2024
Pharmaceutical
USA-based Pelage Pharmaceuticals, a clinical-stage regenerative medicine company developing treatments for hair loss, has closed a $16.75 million Series A financing. 27 February 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics License Application (sBLA) submitted by Denmark's Genmab and US pharma major AbbVie for Epkinly (epcoritamab-bysp). 27 February 2024
Biotechnology
Chinese oncology specialist BeiGene has ended its collaboration with privately-held Shoreline Biosciences. 27 February 2024
Biotechnology
US clinical-stage cell therapy developer Vittoria Biotherapeutics today said that accomplished life sciences leader, Rosemary Mazanet, has joined the company as chief medical officer. 27 February 2024
Biotechnology
A new partnership will see Japanese pharma major Takeda and India’s Biological E (BE) working together to accelerate access to Qdenga (dengue vaccine). 27 February 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved the marketing application for Exblifep (cefepime/enmetazobactam), submitted by Franco-German firm Allecra Therapeutics. 27 February 2024
Pharmaceutical
When James Burt, the chief executive of lifecycle management healthcare company Pharmanovia, looks back at the mood in the pharma industry in 2023, he is happy to say that he is already experiencing a greater sense of optimism in 2024. 27 February 2024
Biotechnology
Further expanding its therapeutic range, Danish diabetes and obesity giant Novo Nordisk has entered into a collaboration and licensing agreement with US biotech Neomorph to discover, develop and commercialize molecular glue degraders beyond oncology. 27 February 2024
Pharmaceutical
Japanese drugmaker Shionogi says it has submitted a marketing approval application for the digital therapeutic app SDT-001, for commercialization and sale in Japan. 27 February 2024
Pharmaceutical
Swedish immunology company InDex Pharmaceuticals late yesterday announced that the development of cobitolimod is discontinued. 27 February 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics today announced the closing of its successful £40.5 million ($51.4 million) Series A financing. 27 February 2024
Pharmaceutical
California’s Tarsus Pharmaceuticals has announced positive topline results from the Phase IIa CARPO trial. 26 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze